Ioana Baldea

Dr. Ioana Baldea

Physiology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Cluj, Romania
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2019 in Clinical Oral Investigations
Verified
Journal Article
Closed access
PDF file
CBCecilia Bacali
Cecilia Bacali
IBIoana Baldea
Ioana Baldea
MMMarioara Moldovan
Marioara Moldovan
RCRahela CARPA
Rahela CARPA
DODiana Elena Olteanu
Diana Elena Olteanu
FBFlorin Badea
Florin Badea

1 February 2019 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
Gabriela Adriana FilipGabriela Adriana Filip
Gabriela Adriana Filip
BMBianca Moldovan
Bianca Moldovan
IBIoana Baldea
Ioana Baldea
EOElena Diana Olteanu
Elena Diana Olteanu
Ramona SuharoschiRamona Suharoschi
Ramona Suharoschi
LDLuminita David
Luminita David

23 July 2019 in Materials
Verified
Journal Article
Open access
PDF file
CBCecilia Bacali
Cecilia Bacali
MBMindra Eugenia Badea
Mindra Eugenia Badea
MMMarioara Moldovan
Marioara Moldovan
CODRUTA SAROSICODRUTA SAROSI
CODRUTA SAROSI
VNVivi Nastase
Vivi Nastase
MCMariana Constantiniuc
Mariana Constantiniuc
The clinical performances of dental materials depend on their mechanical profiles, determining their long-term deformation and wear resistance. This paper describes a study on the mechanical properties, water absorption and morphological properties of a polymethyl methacrylate (PMMA) resin enriched with graphene-silver nanoparticles (Gr-Ag). Two different concentrations—1 and 2 wt.%—of Gr-Ag were loaded into the PMMA material. For the mechanical characterization, the compression behavior, flexural strength and tensile strength were evaluated. Optical microscopy in polarized light and scanning electron microscopy were used for filler analysis. The filler addition led to an improvement in all mechanical properties, with slight changes being derived from the filler content variation. Gr-Ag use led to an increase in the applied maximum loads. Moreover, 1 wt.% Gr-Ag determined an increase of 174% in the modulus of rupture, which indicates high flexibility.

Verified
Journal Article
Open access
PDF file
VDVlad Dionisie
Vlad Dionisie
Adela CiobanuAdela Ciobanu
Adela Ciobanu
Vlad-Alexandru TomaVlad-Alexandru Toma
Vlad-Alexandru Toma
MMMihnea Costin Manea
Mihnea Costin Manea
IBIoana Baldea
Ioana Baldea
Gabriela Adriana FilipGabriela Adriana Filip
Gabriela Adriana Filip
In recent years, escitalopram (ESC) has been suggested to have different mechanisms of action beyond its well known selective serotonin reuptake inhibition. The aim of this study is to investigate the effects of escitalopram on oxidative stress, apoptosis, brain-derived neurotrophic factor (BDNF), Methyl-CpG-binding protein 2 (MeCP2), and oligodendrocytes number in the brain of chronic unpredictable mild stress-induced depressed rats. The animals were randomised in four groups (8 in each group): control, stress, stress + ESC 5 and stress + ESC 5/10. ESC was administered for 42 days in a fixed dose (5 mg/kg b.w.) or in an up-titration regimen (21 days ESC 5 mg/kg b.w. then 21 days ESC 10 mg/kg b.w.). Sucrose preference test (SPT) and elevated plus maze (EPM) were also performed. ESC improved the percentage of sucrose preference, locomotion and anxiety. ESC5/10 reduced the oxidative damage in the hippocampus and improved the antioxidant defence in the hippocampus and frontal lobe. ESC5/10 lowered caspase 3 activity in the hippocampus. Escitalopram had a modulatory effect on BDNF and the number of oligodendrocytes in the hippocampus and frontal lobe and also improved the MeCP2 expressions. The results confirm the multiple pathways implicated in the pathogenesis of depression and suggest that escitalopram exerts an antidepressant effect via different intricate mechanisms.

1 June 2018 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
IBIoana Baldea
Ioana Baldea
ITIoana Teacoe
Ioana Teacoe
EOElena Diana Olteanu
Elena Diana Olteanu
CVCristina Vaida-Voievod
Cristina Vaida-Voievod
ACAndra Clichici
Andra Clichici
Simona ClichiciSimona Clichici
Simona Clichici

4 October 2025 in Nanomaterials
Verified
Journal Article
Open access
PDF file
IBIoana Baldea
Ioana Baldea
Cristian IacovitaCristian Iacovita
Cristian Iacovita
RGRaul Andrei Gurgu
Raul Andrei Gurgu
AVAlin Stefan Vizitiu
Alin Stefan Vizitiu
VRVlad Răzniceanu
Vlad Răzniceanu
DMDaniela Rodica Mitrea
Daniela Rodica Mitrea
Iron oxide nanoparticles (IONPs) have emerged as key materials in magnetic hyperthermia (MH), a minimally invasive cancer therapy capable of selectively inducing apoptosis, ferroptosis, and other cell death pathways while sparing surrounding healthy tissue. This review synthesizes advances in the design, functionalization, and biomedical application of magnetic nanoparticles (MNPs) for MH, highlighting strategies to optimize heating efficiency, biocompatibility, and tumor targeting. Key developments include tailoring particle size, shape, and composition; doping with metallic ions; engineering multicore nanostructures; and employing diverse surface coatings to improve colloidal stability, immune evasion, and multifunctionality. We discuss preclinical and clinical evidence for MH, its integration with chemotherapy, radiotherapy, and immunotherapy, and emerging theranostic applications enabling simultaneous imaging and therapy. Special attention is given to the role of MNPs in immunogenic cell death induction and metastasis prevention, as well as novel concepts for circulating tumor cell capture. Despite promising results in vitro and in vivo, clinical translation remains limited by insufficient tumor accumulation after systemic delivery, safety concerns, and a lack of standardized treatment protocols. Future progress will require interdisciplinary innovations in nanomaterial engineering, active targeting technologies, and real-time treatment monitoring to fully integrate MH into multimodal cancer therapy and improve patient outcomes.